LONDON (ShareCast) - (Sharecast News) - Analysts at Canaccord Genuity lowered their target price on chemicals business Synthomer from 350.0p to 300.0p on Wednesday as it effectively pushed out its expectations for the group's recovery by 12 months.
Canaccord Genuity said the September 2023 recapitalisation of Synthomer had left the group "well-placed to survive the current extended downturn". However, the outlook for the current year was still for limited progress.

"We are moving numbers to the right, effectively pushing the recovery out by a year; we now expect nearly all of the improvement in 2024E to be self-help, with better figures coming next year," said Canaccord Genuity. "The impact on our valuation is more modest, given that we now look well set for a sustained recovery in the chemicals industry, and we are effectively pushing out our valuation by one year".

The Canadian bank noted that Given Synthomer's equity gearing - at the current share price, the equity value sits at around 28% of the enterprise value - even a "quite modest" improvement in outlook or the successful execution of an asset sale could have "a very material impact" on the share price.













Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE